Orna Collaborates with Vertex to Develop Gene Therapies for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Shots:
- Orna & Vertex have entered into a 3yrs. strategic research collaboration to utilize the former’s LNP delivery solutions for supporting the development of next-gen. gene editing therapies for SCD & TDT, with Vertex funding the partnership
- As per the terms, Orna will get $65M upfront (incl. investment in the form of a convertible note), up to $635M as preclinical, research, development, regulatory & commercial milestones plus net-sales-based tiered royalties
- Moreover, Orna is also entitled for an option fees & milestones of ~$365M per candidate for up to 10 additional products, if Vertex exercises its option of collaboration expansion to other indications
Ref: Orna Therapeutics | Image: Orna Therapeutics & Vertex Pharmaceuticals
Related News: Merck Collaborated with Orna Therapeutics to Advance RNA Therapies for Infectious Disease and Oncology
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
